Director / PDMR Shareholding

EKF Diagnostics Holdings plc

(“EKF” or the “Company”)


Notification of transactions by Persons Discharging Managerial Responsibilities

and persons closely associated with them


EKF Diagnostics Holdings plc (AIM: EKF) announces that on 11 July 2016, the Company was notified that Harwood Capital LLP ("Harwood") acquired 3,057,940 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") as investment manager to North Atlantic Smaller Companies Investment Trust PLC ("NAIT"). Christopher Mills, the Company's Non-Executive Chairman, is a partner and Chief Investment Officer of Harwood and a director and shareholder in NAIT.


Following the above transaction, which was completed on 8 July 2016 at a price of 14.9653 pence per share, NAIT's interest is now in 78,100,000 Ordinary Shares, representing 16.82% of the Company's issued share capital. The interests of Oryx International Growth Fund Limited ("Oryx", whose investment adviser is Harwood) remains as previously disclosed in 40,000,000 Ordinary Shares, representing 8.62% of the Company's issued share capital. Mr Mills is also a director and shareholder in Oryx.


The total indirect beneficial interest of Mr Mills is, following the above transaction, therefore now in 118,100,000 Ordinary Shares, representing 25.44% of the Company's issued share capital.



EKF Diagnostics Holdings plc   

Tel: 029 2071 0570

Julian Baines, CEO 


Richard Evans, FD & COO




Panmure Gordon (UK) Limited

Tel: 020 7886 2500

Paul Fincham


Peter Steel




Walbrook PR Limited

Tel: 020 7933 8780 or

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303





This notification is made in accordance with the requirements of the EU Market Abuse Regulation. Further details:


Initial notification / amendment: Initial

Ordinary Shares Identification Code: ISIN GB0031509804

Aggregated information: N/A

Place of the transaction: London Stock Exchange, AIM (XLON)

Back to ListingPreviousNext